Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.38
ALXN's Cash to Debt is ranked lower than
88% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. ALXN: 0.38 )
Ranked among companies with meaningful Cash to Debt only.
ALXN' s Cash to Debt Range Over the Past 10 Years
Min: 0.4  Med: 2.96 Max: No Debt
Current: 0.38
Equity to Asset 0.63
ALXN's Equity to Asset is ranked lower than
55% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ALXN: 0.63 )
Ranked among companies with meaningful Equity to Asset only.
ALXN' s Equity to Asset Range Over the Past 10 Years
Min: 0.04  Med: 0.68 Max: 0.95
Current: 0.63
0.04
0.95
Interest Coverage 11.24
ALXN's Interest Coverage is ranked lower than
88% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALXN: 11.24 )
Ranked among companies with meaningful Interest Coverage only.
ALXN' s Interest Coverage Range Over the Past 10 Years
Min: 14.38  Med: 143.66 Max: 292.93
Current: 11.24
14.38
292.93
F-Score: 3
Z-Score: 4.56
M-Score: -2.17
WACC vs ROIC
13.81%
2.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 20.61
ALXN's Operating margin (%) is ranked higher than
85% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. ALXN: 20.61 )
Ranked among companies with meaningful Operating margin (%) only.
ALXN' s Operating margin (%) Range Over the Past 10 Years
Min: -10370.21  Med: 25.18 Max: 38.89
Current: 20.61
-10370.21
38.89
Net-margin (%) 5.54
ALXN's Net-margin (%) is ranked higher than
74% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. ALXN: 5.54 )
Ranked among companies with meaningful Net-margin (%) only.
ALXN' s Net-margin (%) Range Over the Past 10 Years
Min: -10220.86  Med: 17.12 Max: 76.31
Current: 5.54
-10220.86
76.31
ROE (%) 2.26
ALXN's ROE (%) is ranked higher than
77% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. ALXN: 2.26 )
Ranked among companies with meaningful ROE (%) only.
ALXN' s ROE (%) Range Over the Past 10 Years
Min: -136.75  Med: 14.48 Max: 63.11
Current: 2.26
-136.75
63.11
ROA (%) 1.50
ALXN's ROA (%) is ranked higher than
79% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. ALXN: 1.50 )
Ranked among companies with meaningful ROA (%) only.
ALXN' s ROA (%) Range Over the Past 10 Years
Min: -45.22  Med: 9.66 Max: 46.71
Current: 1.5
-45.22
46.71
ROC (Joel Greenblatt) (%) 58.07
ALXN's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. ALXN: 58.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALXN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -902.5  Med: 43.22 Max: 173.86
Current: 58.07
-902.5
173.86
Revenue Growth (3Y)(%) 39.50
ALXN's Revenue Growth (3Y)(%) is ranked higher than
88% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. ALXN: 39.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALXN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -70.5  Med: 39.10 Max: 498.1
Current: 39.5
-70.5
498.1
EBITDA Growth (3Y)(%) 52.40
ALXN's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. ALXN: 52.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALXN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.1  Med: 29.50 Max: 72.8
Current: 52.4
-10.1
72.8
EPS Growth (3Y)(%) 52.80
ALXN's EPS Growth (3Y)(%) is ranked higher than
92% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ALXN: 52.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALXN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -15.5  Med: 14.30 Max: 76.4
Current: 52.8
-15.5
76.4
» ALXN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

ALXN Guru Trades in Q4 2014

Ray Dalio 18,513 sh (New)
Joel Greenblatt 85,974 sh (+4665.74%)
Ron Baron 18,366 sh (+41.92%)
Pioneer Investments 30,795 sh (+0.97%)
Frank Sands 5,267,903 sh (-0.82%)
Jim Simons 152,552 sh (-26.00%)
Paul Tudor Jones 1,487 sh (-52.34%)
Andreas Halvorsen 390,271 sh (-82.25%)
» More
Q1 2015

ALXN Guru Trades in Q1 2015

Lee Ainslie 1,350 sh (New)
Ron Baron 41,163 sh (+124.13%)
Paul Tudor Jones 3,231 sh (+117.28%)
Jim Simons 313,952 sh (+105.80%)
Ray Dalio 29,099 sh (+57.18%)
Pioneer Investments 31,941 sh (+3.72%)
Andreas Halvorsen Sold Out
Frank Sands 5,204,296 sh (-1.21%)
Joel Greenblatt 23,261 sh (-72.94%)
» More
Q2 2015

ALXN Guru Trades in Q2 2015

Andreas Halvorsen 201,756 sh (New)
Mario Gabelli 1,415 sh (New)
David Swensen 319,273 sh (New)
Ron Baron 69,764 sh (+69.48%)
Frank Sands 6,519,546 sh (+25.27%)
Lee Ainslie 1,600 sh (+18.52%)
Pioneer Investments 32,062 sh (+0.38%)
Ray Dalio Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones 1,501 sh (-53.54%)
Jim Simons 13,442 sh (-95.72%)
» More
Q3 2015

ALXN Guru Trades in Q3 2015

Jim Simons 689,542 sh (+5029.76%)
Pioneer Investments 32,062 sh (unchged)
Paul Tudor Jones Sold Out
Lee Ainslie Sold Out
Mario Gabelli Sold Out
David Swensen Sold Out
Andreas Halvorsen Sold Out
Frank Sands 6,379,857 sh (-2.14%)
Ron Baron 32,624 sh (-53.24%)
» More
» Details

Insider Trades

Latest Guru Trades with ALXN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Alexion Pharmaceuticals Inc

Baron Funds Comments on Alexion Pharmaceuticals - Feb 08, 2016

We also sold our Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) position in the third quarter to harvest a tax loss. We rebuilt our position this quarter. Alexion is the premier orphan disease company, whose lead product Soliris is a lifesaving medicine for both Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The company has expanded its efforts in orphan diseases (particularly ones with high unmet needs) with the acquisition of Strensiq for Hypophosphatasia (HPP) and Kanuma for Lysosomal Acid Lipase Deficiency (LAL-D), both of which are approved or in the final stages of approval for launch worldwide.



From the Baron Funds Opportunity Fund fourth quarter 2015 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals Inc. - Nov 10, 2015

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is the premier orphan disease company, whose lead product Soliris is a lifesaving medicine for both Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical hemolytic uremic syndrome (aHUS). The company has expanded its efforts in orphan diseases (particularly ones with high unmet needs) with the acquisition of Strensiq for HPP (Hypophosphatasia) and Kanuma for LAL-D (Lysosomal Acid Lipase Deficiency), both of which are approved or in the final stages of approval for launch worldwide. The company recently announced the delay of Strensiq approval by the FDA for manufacturing related issues. With greater uncertainty surrounding the approval of Strensiq, and overall sentiment on the biotech industry souring, we reduced our exposure to the industry and sold our position in Alexion.





From the Baron Opportunity Fund third quarter 2015 letter.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals Inc. - Aug 19, 2015

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is a biopharmaceutical company that pioneered the “orphan disease” space by focusing on delivering life-transforming treatments for patients with devastating (life threatening) and ultra-rare (or orphan) diseases. Alexion is a leader in disease education and diagnostic initiatives to ensure that patients for its drugs are rapidly and accurately diagnosed. We believe Alexion’s first commercial drug, known as Soliris, which is used to treat paroxysmal nocturnal hemoglobinuria (called PNH) and atypical hemolytic uremic syndrome (referred to as aHUS), continues to possess a large global growth opportunity. Alexion has a pipeline of additional rare-disease treatments, and recently acquired Synageva, a company with two additional drugs for treating rare and devastating metabolic diseases, as well as a pipeline of other compounds, giving the company what we believe to be the most robust rare disease pipeline in the biotech industry.





From Baron Funds’ second quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Alexion Pharmaceuticals Inc

Baron Funds Comments on Alexion Pharmaceuticals Guru stock highlight
We also sold our Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) position in the third quarter to harvest a tax loss. We rebuilt our position this quarter. Alexion is the premier orphan disease company, whose lead product Soliris is a lifesaving medicine for both Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The company has expanded its efforts in orphan diseases (particularly ones with high unmet needs) with the acquisition of Strensiq for Hypophosphatasia (HPP) and Kanuma for Lysosomal Acid Lipase Deficiency (LAL-D), both of which are approved or in the final stages of approval for launch worldwide. Read more...
Weekly CFO Sells Highlight: Tyson Foods, Alexion Pharmaceuticals, Gilead Sciences Recent insider sales from company CFOs
According to GuruFocus Insider Data, the recent CFO sales were: Tyson Foods Inc. (NYSE:TSN), Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Gilead Sciences Inc. (NASDAQ:GILD). Read more...
Alexion Pharmaceuticals Loses Position in Swensen's Portfolio Guru sells LendingClub, Antero Resources and Inogen, buys Atara Biotherapeutics and Tesaro
David Swensen (Trades, Portfolio) has been the chief investment officer of Yale University's endowment fund since 1985. He is responsible for managing and investing the university's endowment assets and investment funds. Here are his most weighted stocks that got new positions or lost their positions in the portfolio during the third quarter. Read more...
Baron Funds Comments on Alexion Pharmaceuticals Inc. Guru stock highlight
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is the premier orphan disease company, whose lead product Soliris is a lifesaving medicine for both Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical hemolytic uremic syndrome (aHUS). The company has expanded its efforts in orphan diseases (particularly ones with high unmet needs) with the acquisition of Strensiq for HPP (Hypophosphatasia) and Kanuma for LAL-D (Lysosomal Acid Lipase Deficiency), both of which are approved or in the final stages of approval for launch worldwide. The company recently announced the delay of Strensiq approval by the FDA for manufacturing related issues. With greater uncertainty surrounding the approval of Strensiq, and overall sentiment on the biotech industry souring, we reduced our exposure to the industry and sold our position in Alexion. Read more...
David Swensen Buys Stake in Vanguard MSCI Emerging Markets ETF
In 30 years as chief investment officer at Yale University, David Swensen (Trades, Portfolio) has been quite successful. In the last decade, he has enjoyed an annual return of more than 17.2% on his investments. In his personal investments, Swensen applies knowledge he has gained in that role as well as in his six years on Wall Street prior to taking the job at Yale Read more...
Baron Funds Comments on Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is a biopharmaceutical company that pioneered the “orphan disease” space by focusing on delivering life-transforming treatments for patients with devastating (life threatening) and ultra-rare (or orphan) diseases. Alexion is a leader in disease education and diagnostic initiatives to ensure that patients for its drugs are rapidly and accurately diagnosed. We believe Alexion’s first commercial drug, known as Soliris, which is used to treat paroxysmal nocturnal hemoglobinuria (called PNH) and atypical hemolytic uremic syndrome (referred to as aHUS), continues to possess a large global growth opportunity. Alexion has a pipeline of additional rare-disease treatments, and recently acquired Synageva, a company with two additional drugs for treating rare and devastating metabolic diseases, as well as a pipeline of other compounds, giving the company what we believe to be the most robust rare disease pipeline in the biotech industry. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 111.05
ALXN's P/E(ttm) is ranked lower than
86% of the 374 Companies
in the Global Biotechnology industry.

( Industry Median: 35.73 vs. ALXN: 111.05 )
Ranked among companies with meaningful P/E(ttm) only.
ALXN' s P/E(ttm) Range Over the Past 10 Years
Min: 13.92  Med: 74.50 Max: 1113.68
Current: 111.05
13.92
1113.68
Forward P/E 18.73
ALXN's Forward P/E is ranked lower than
55% of the 347 Companies
in the Global Biotechnology industry.

( Industry Median: 16.47 vs. ALXN: 18.73 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 110.94
ALXN's PE(NRI) is ranked lower than
85% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 33.50 vs. ALXN: 110.94 )
Ranked among companies with meaningful PE(NRI) only.
ALXN' s PE(NRI) Range Over the Past 10 Years
Min: 13.96  Med: 74.59 Max: 1058
Current: 110.94
13.96
1058
P/B 3.71
ALXN's P/B is ranked lower than
66% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.49 vs. ALXN: 3.71 )
Ranked among companies with meaningful P/B only.
ALXN' s P/B Range Over the Past 10 Years
Min: 3.71  Med: 10.65 Max: 162.14
Current: 3.71
3.71
162.14
P/S 11.32
ALXN's P/S is ranked lower than
57% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. ALXN: 11.32 )
Ranked among companies with meaningful P/S only.
ALXN' s P/S Range Over the Past 10 Years
Min: 11.43  Med: 22.62 Max: 1115
Current: 11.32
11.43
1115
PFCF 56.14
ALXN's PFCF is ranked lower than
74% of the 265 Companies
in the Global Biotechnology industry.

( Industry Median: 27.59 vs. ALXN: 56.14 )
Ranked among companies with meaningful PFCF only.
ALXN' s PFCF Range Over the Past 10 Years
Min: 40  Med: 63.20 Max: 99999999.99
Current: 56.14
40
99999999.99
POCF 37.28
ALXN's POCF is ranked lower than
64% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 25.75 vs. ALXN: 37.28 )
Ranked among companies with meaningful POCF only.
ALXN' s POCF Range Over the Past 10 Years
Min: 33.16  Med: 50.36 Max: 83.87
Current: 37.28
33.16
83.87
EV-to-EBIT 73.53
ALXN's EV-to-EBIT is ranked lower than
87% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 20.26 vs. ALXN: 73.53 )
Ranked among companies with meaningful EV-to-EBIT only.
ALXN' s EV-to-EBIT Range Over the Past 10 Years
Min: -185.3  Med: 57.90 Max: 194.4
Current: 73.53
-185.3
194.4
EV-to-EBITDA 63.26
ALXN's EV-to-EBITDA is ranked lower than
84% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 17.11 vs. ALXN: 63.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALXN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -243  Med: 54.40 Max: 152.2
Current: 63.26
-243
152.2
PEG 2.21
ALXN's PEG is ranked higher than
57% of the 90 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. ALXN: 2.21 )
Ranked among companies with meaningful PEG only.
ALXN' s PEG Range Over the Past 10 Years
Min: 0.68  Med: 1.45 Max: 3.61
Current: 2.21
0.68
3.61
Shiller P/E 178.59
ALXN's Shiller P/E is ranked lower than
90% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 45.84 vs. ALXN: 178.59 )
Ranked among companies with meaningful Shiller P/E only.
ALXN' s Shiller P/E Range Over the Past 10 Years
Min: 178.59  Med: 370.04 Max: 5207
Current: 178.59
178.59
5207
Current Ratio 3.23
ALXN's Current Ratio is ranked lower than
60% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. ALXN: 3.23 )
Ranked among companies with meaningful Current Ratio only.
ALXN' s Current Ratio Range Over the Past 10 Years
Min: 2.3  Med: 7.98 Max: 52.92
Current: 3.23
2.3
52.92
Quick Ratio 2.93
ALXN's Quick Ratio is ranked lower than
60% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ALXN: 2.93 )
Ranked among companies with meaningful Quick Ratio only.
ALXN' s Quick Ratio Range Over the Past 10 Years
Min: 2.03  Med: 7.66 Max: 52.92
Current: 2.93
2.03
52.92
Days Inventory 348.17
ALXN's Days Inventory is ranked lower than
89% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. ALXN: 348.17 )
Ranked among companies with meaningful Days Inventory only.
ALXN' s Days Inventory Range Over the Past 10 Years
Min: 202.61  Med: 330.15 Max: 959.95
Current: 348.17
202.61
959.95
Days Sales Outstanding 74.69
ALXN's Days Sales Outstanding is ranked lower than
56% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. ALXN: 74.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALXN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.74  Med: 110.57 Max: 451.45
Current: 74.69
70.74
451.45
Days Payable 73.56
ALXN's Days Payable is ranked higher than
58% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. ALXN: 73.56 )
Ranked among companies with meaningful Days Payable only.
ALXN' s Days Payable Range Over the Past 10 Years
Min: 44.39  Med: 92.91 Max: 494.52
Current: 73.56
44.39
494.52

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 3.13
ALXN's Price/Projected FCF is ranked higher than
50% of the 296 Companies
in the Global Biotechnology industry.

( Industry Median: 3.14 vs. ALXN: 3.13 )
Ranked among companies with meaningful Price/Projected FCF only.
ALXN' s Price/Projected FCF Range Over the Past 10 Years
Min: 3.59  Med: 7.32 Max: 142.22
Current: 3.13
3.59
142.22
Price/Median PS Value 0.67
ALXN's Price/Median PS Value is ranked higher than
66% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: 0.89 vs. ALXN: 0.67 )
Ranked among companies with meaningful Price/Median PS Value only.
ALXN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.37  Med: 1.11 Max: 43.91
Current: 0.67
0.37
43.91
Price/Peter Lynch Fair Value 4.44
ALXN's Price/Peter Lynch Fair Value is ranked lower than
56% of the 111 Companies
in the Global Biotechnology industry.

( Industry Median: 1.67 vs. ALXN: 4.44 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ALXN' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.56  Med: 2.83 Max: 5.09
Current: 4.44
0.56
5.09
Earnings Yield (Greenblatt) (%) 1.38
ALXN's Earnings Yield (Greenblatt) (%) is ranked higher than
74% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. ALXN: 1.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALXN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 1.50 Max: 2.4
Current: 1.38
0.5
2.4
Forward Rate of Return (Yacktman) (%) 44.25
ALXN's Forward Rate of Return (Yacktman) (%) is ranked higher than
91% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. ALXN: 44.25 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ALXN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -18.5  Med: 0.25 Max: 75.6
Current: 44.25
-18.5
75.6

More Statistics

Revenue(Mil) $2604
EPS $ 0.76
Beta1.60
Short Percentage of Float4.14%
52-Week Range $130.51 - 208.88
Shares Outstanding(Mil)225.32

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 2,606 3,146 3,916 4,668
EPS($) 4.36 5.34 7.28 8.96
EPS without NRI($) 4.36 5.34 7.28 8.96

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AXP.Germany, ALXN.Switzerland, 0QZM.UK,
Alexion Pharmaceuticals Inc is a Delaware based company, incorporated in 1992. The Company is a biopharmaceutical company serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria, an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome, an ultra-rare and life-threatening genetic disease. The Company is also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism. It operates in United States, Europe and Asia Pacific. It competes with companies that produce and market synthetic compounds and with specialized biotechnology firms in the United States, Europe and in other countries and regions, as well as a growing number of large pharmaceutical companies that are developing biotechnology products. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of products and product candidates, including Soliris, are subject to extensive regulation by governmental authorities in the United States, the European Union and other territories.
» More Articles for ALXN

Headlines

Articles On GuruFocus.com
Baron Funds Comments on Alexion Pharmaceuticals Feb 08 2016 
Weekly CFO Sales Highlight: H&R Block, DISH Network, Alexion Pharmaceuticals Jan 03 2016 
Weekly CFO Sells Highlight: Tyson Foods, Alexion Pharmaceuticals, Gilead Sciences Dec 13 2015 
Weekly Insider Sells Highlights: CDW, Twitter, P&G, Alexion Pharmaceuticals Dec 10 2015 
Alexion Pharmaceuticals Loses Position in Swensen's Portfolio Dec 03 2015 
Jim Simons' Largest Adds of the 3rd Quarter Nov 13 2015 
Baron Funds Comments on Alexion Pharmaceuticals Inc. Nov 10 2015 
Frank Sands Shows Bold Side in Second-Quarter Trades Sep 13 2015 
David Swensen Buys Stake in Vanguard MSCI Emerging Markets ETF Aug 19 2015 
Baron Funds Comments on Alexion Pharmaceuticals Inc. Aug 19 2015 

More From Other Websites
Biotech ETFs Slide as Stocks Report Mixed Q4 Results Feb 09 2016
ALEXION PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 08 2016
Alexion Pharmaceuticals' Big Top Foreshadows Big Drop Feb 08 2016
How to Play the Biotech Selloff Feb 05 2016
Alexion Pharmaceuticals, Inc. Earnings Analysis: 2015 By the Numbers Feb 04 2016
Alexion to Present at the Leerink Partners 5th Annual Global Healthcare Conference Feb 04 2016
Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.3% Feb 04 2016
Lightning Round: This energy stock goes higher Feb 03 2016
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 03 2016
Edited Transcript of ALXN earnings conference call or presentation 3-Feb-16 3:00pm GMT Feb 03 2016
Alexion Pharmaceuticals Rides the Earnings Roller Coaster Feb 03 2016
Alexion Misses on Earnings and Revenues in Q4, Gives View Feb 03 2016
[$$] Alexion Pharmaceuticals Revenue Jumps, Profit Falls Feb 03 2016
Biotechnology Stocks Technical Snapshot -- Geron, ACADIA Pharma, Alexion Pharma, and Illumina Feb 03 2016
Alexion (ALXN) Misses on Q4 Earnings and Revenues Feb 03 2016
Morning Movers: Alexion, Merck Drop on Earnings; Atwood Oceanics Gains Feb 03 2016
Q4 2015 Alexion Pharmaceuticals Inc Earnings Release - Before Market Open Feb 03 2016
Alexion tops 4Q profit forecasts Feb 03 2016
Alexion beats 4Q profit forecasts Feb 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK